Millions of Eye Drops Recalled Nationwide Over Sterility Concerns

K.C. Pharmaceuticals has recalled over three million bottles of eye drops sold nationwide at major retailers, a voluntary action initiated on March 3 due to concerns the products may not be sterile. The U.S. Food and Drug Administration (FDA) has since classified the event, providing an official risk assessment for consumers.

This urgent eye drops recall affects a wide array of private-label products sold at stores including CVS, Walgreens, and Kroger, prompting immediate safety recommendations for the public. Consumers are urged to identify and stop using the affected products to mitigate potential health risks. While the FDA has stated the probability of serious adverse health consequences is remote, the "lack of assurance of sterility" means the products cannot be guaranteed to be free from potentially harmful microorganisms, a critical standard for any ophthalmic solution.

What We Know So Far

• K.C. Pharmaceuticals initiated a voluntary recall of more than 3.1 million bottles of eye drops on March 3, 2026, citing a "lack of assurance of sterility," according to an FDA enforcement report.
• The FDA officially categorized the action as a Class II recall on March 31, 2026. This classification indicates that use of the product may cause temporary or medically reversible adverse health consequences.
• The recalled eye drops were distributed across the country and sold under various store-brand names at major retailers such as Walgreens, CVS, Kroger, and Rite Aid, as reported by WALB News 10.
• According to a report from the New York Post, no confirmed contamination has been found in the products to date, and it remains unclear if any adverse health events have been linked to their use.
• The FDA states that with a Class II recall, the probability of serious adverse health consequences is remote.

Why Were These Eye Drops Recalled?

The core issue prompting this extensive recall is a "lack of assurance of sterility." This technical term signifies a failure in the manufacturing process, meaning K.C. Pharmaceuticals could not definitively guarantee that its production environment and procedures prevented the introduction of infection-causing microbes into the eye drops. For ophthalmic products, which are applied directly to the sensitive tissues of the eye, sterility is not a guideline but an absolute requirement. The eye's mucous membranes can be a direct pathway for bacteria and fungi to cause serious infections, potentially leading to vision damage.